ISTA Pharmaceuticals Inc.
15295 Alton Parkway
Irvine,
CA 92618
United States - Map
Phone: 949-788-6000
Fax: 949-788-6010
Web Site: http://www.istavision.com
| ISTA Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye in the United States. The company offers Xibrom for the treatment of inflammation and pain following cataract surgery; Istalol for the treatment of glaucoma; and Vitrase for use as a spreading agent. Its developing products include Bepotastine ophthalmic solution for allergic conjunctivitis; T-Pred, a Phase III clinical trial product candidate for the treatment of steroid-responsive inflammatory ocular conditions; Ecabet Sodium, a Phase IIb clinical trial product, for the treatment of dry eye syndrome; and Bepotastine nasal for the treatment of allergic rhinitis. The companys products developing products also include a steroid product candidate to treat ocular inflammation; iganidipine to enhance ocular nerve blood flow; and a formulation of latanoprost for the treatment of glaucoma. It sells its products primarily to drug wholesalers, retailers, and distributors, including chain drug stores, hospitals, clinics, government agencies, and managed healthcare providers. ISTA Pharmaceuticals was formerly known as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in March 2000. The company was founded in 1992 and is headquartered in Irvine, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Vicente Anido Jr., Ph.D., 56
Chief Exec. Officer, Pres |
$
730.00K |
$
0 | Mrs. Lauren P. Silvernail , 50
Chief Financial Officer, Chief Accounting Officer and VP of Corp. Devel. |
$
391.00K |
$
0 | Mr. Thomas A. Mitro , 51
VP of Sales & Marketing |
$
398.00K |
$
0 | Mr. Marvin J. Garrett , 58
VP of Regulatory Affairs, Quality and Compliance |
$
374.00K |
$
0 | Dr. Timothy R. McNamara Pharm.D, 53
VP of Clinical Research & Medical Affairs |
$
352.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
